Yep, from what I recall the company has guided “2-6 months” in prior announcements without explicitly using class 1 or class 2 terminology.
This could easily be taken as an expectation of greater than two months but less than six, i.e. expecting a class 2 but not expecting it would take a full six months.
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-50
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.37 |
Change
0.120(9.64%) |
Mkt cap ! $1.512B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $15.62M | 11.60M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 35379 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.37 | 16424 | 11 |
View Market Depth
| Last trade - 15.35pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |